The COA evaluated 49 top acute care hospitals with a disproportionately large number of uninsured and under-insured patients. Based on the assumption that these hospitals gained a 34.7 percent discount on the drugs, markups ranged from 3.2 percent to 11.3 percent, according to the report.
Cost variation happened within each hospital, too, depending on each patient’s insurer.
“Some hospitals and hospital systems have come to treat 340B less as an assistance program and more as a profit-center,” the Center for Medicine in the Public Interest’s president, Peter Pitts, and its chief science policy officer, Robert Popovian, PharmD, wrote in a Sept. 12 report. “Today, there is ever-increasing evidence of the program’s out-of-control scope and a growing chorus from all corners of government who are finally beginning to see the 340B drug discount program for what it has become — a moneymaker for hospitals wrapped in the rhetoric of healthcare compassion.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
